Literature DB >> 17589921

In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines.

Dennis Hoffmann1, Wibke Bayer, Oliver Wildner.   

Abstract

AIM: To evaluate whether intratumoral expression of measles virus fusogenic membrane glycoproteins H and F (MV-FMG), encoded by an adenovirus vector Ad.MV-H/F, alone or in combination with local coexpression of cytokines (IL-2, IL-12, IL-18, IL-21 or GM-CSF), can serve as a platform for inducing tumor-specific immune responses in colon cancer.
METHODS: We used confocal laser scanning microscopy and flow cytometry to analyze cell-cell fusion after expression of MV-FMG by dye colocalization. In a syngeneic bilateral subcutaneous MC38 and Colon26 colon cancer model in C57BL/6 and BALB/c mice, we assessed the effect on both the directly vector-treated tumor as well as the contralateral, not directly vector-treated tumor. We assessed the induction of a tumor-specific cytotoxic T lymphocyte (CTL) response with a lactate dehydrogenase (LDH) release assay.
RESULTS: We demonstrated in vitro that transduction of MC38 and Colon26 cells with Ad.MV-H/F resulted in dye colocalization, indicative of cell-cell fusion. In addition, in the syngeneic bilateral tumor model we demonstrated a significant regression of the directly vector-inoculated tumor upon intratumoral expression of MV-FMG alone or in combination with the tested cytokines. We observed the highest anti-neoplastic efficacy with MV-FMG and IL-21 coexpression. The degree of tumor regression of the not directly vector-treated tumor correlated with the anti-neoplastic response of the directly vector-treated tumor. This regression was mediated by a tumor-specific CTL response.
CONCLUSION: Our data indicate that intratumoral expression of measles virus fusogenic membrane glycoproteins is a promising tool both for direct tumor treatment as well as for tumor vaccination approaches that can be further enhanced by cytokine coexpression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17589921      PMCID: PMC4172612          DOI: 10.3748/wjg.v13.i22.3063

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  56 in total

1.  Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial.

Authors:  Wei-Chen Lee; Hui-Chuan Wang; Chien-Fu Hung; Pei-Fang Huang; Chen-Rong Lia; Miin-Fu Chen
Journal:  J Immunother       Date:  2005 Sep-Oct       Impact factor: 4.456

2.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

3.  Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression.

Authors:  S Shimura; G Yang; S Ebara; T M Wheeler; A Frolov; T C Thompson
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

4.  IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.

Authors:  Rachel Ettinger; Gary P Sims; Anna-Marie Fairhurst; Rachel Robbins; Yong Sing da Silva; Rosanne Spolski; Warren J Leonard; Peter E Lipsky
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

5.  Measles virus fusion protein is palmitoylated on transmembrane-intracytoplasmic cysteine residues which participate in cell fusion.

Authors:  M Caballero; J Carabaña; J Ortego; R Fernández-Muñoz; M L Celma
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  In vivo immunomodulation following intradermal injection with DNA encoding IL-18.

Authors:  L Kremer; L Dupré; I Wolowczuk; C Locht
Journal:  J Immunol       Date:  1999-09-15       Impact factor: 5.422

7.  Moesin is not a receptor for measles virus entry into mouse embryonic stem cells.

Authors:  Y Doi; M Kurita; M Matsumoto; T Kondo; T Noda; S Tsukita; S Tsukita; T Seya
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  The human CD46 molecule is a receptor for measles virus (Edmonston strain).

Authors:  R E Dörig; A Marcil; A Chopra; C D Richardson
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

9.  Interleukin 2-activated cytotoxic lymphocytes in cancer therapy.

Authors:  E A Grimm; S K Jacobs; L A Lanza; G Melin; J A Roth; D J Wilson
Journal:  Symp Fundam Cancer Res       Date:  1986

10.  High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors.

Authors:  T Leimig; M Brenner; J Ramsey; E Vanin; M Blaese; D Dilloo
Journal:  Hum Gene Ther       Date:  1996-06-20       Impact factor: 5.695

View more
  9 in total

1.  Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time.

Authors:  Sai V Vemula; Omar Amen; Jacqueline M Katz; Ruben Donis; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Virus Res       Date:  2013-09-17       Impact factor: 3.303

Review 2.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

3.  Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytia.

Authors:  Dennis Hoffmann; Thomas Grunwald; Wibke Bayer; Oliver Wildner
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

4.  Intravital imaging of the effects of 5-fluorouracil on the murine liver microenvironment using 2-photon laser scanning microscopy.

Authors:  Masato Okigami; Koji Tanaka; Yasuhiro Inoue; Susumu Saigusa; Yoshinaga Okugawa; Yuji Toiyama; Yasuhiko Mohri; Masato Kusunoki
Journal:  Oncol Lett       Date:  2016-02-23       Impact factor: 2.967

Review 5.  Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic.

Authors:  Joshua Del Papa; Ryan G Clarkin; Robin J Parks
Journal:  Cancer Gene Ther       Date:  2020-07-01       Impact factor: 5.987

6.  A Double-Switch Cell Fusion-Inducible Transgene Expression System for Neural Stem Cell-Based Antiglioma Gene Therapy.

Authors:  Yumei Luo; Detu Zhu; Dang Hoang Lam; Juan Huang; Yi Tang; Xitu Luo; Shu Wang
Journal:  Stem Cells Int       Date:  2015-05-05       Impact factor: 5.443

7.  Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer.

Authors:  C M Wong; L A Nash; J Del Papa; K L Poulin; T Falls; J C Bell; R J Parks
Journal:  Cancer Gene Ther       Date:  2016-10-14       Impact factor: 5.987

Review 8.  Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents.

Authors:  Joshua Del Papa; Robin J Parks
Journal:  Viruses       Date:  2017-01-19       Impact factor: 5.048

9.  Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.

Authors:  Olga V Matveeva; Zong S Guo; Svetlana A Shabalina; Peter M Chumakov
Journal:  Mol Ther Oncolytics       Date:  2015-07-22       Impact factor: 7.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.